Tweet Some might say I’ve been a bit absent from this forum, and it’s true. However, plenty of work has been done by a team so large there wasn’t enough space on the latest abstract submission to MSToronto2026 to include even the most involved, since…
By Angel Blair I think it goes without saying how important one’s overall health is. Though when we talk about health and wellness, we often just think of the physical aspects. But a crucial part of our well-being relies on … Continue reading → Source:…
Two commonly used disease-modifying treatments seem to be equally effective for most people with late-onset multiple sclerosis (LOMS), according to a real-world analysis. Anti-CD20 therapies, designed to reduce immune cells that produce disease-driving antibodies, and S1P receptor modulators, which work by preventing pro-inflammatory immune cells from…
A new type of MRI scan may be able to distinguish active multiple sclerosis (MS) lesions from chronic lesions — without the need for injected contrast dye — while also offering clues about how lesions may evolve over time, a new study reports. By combining…
Tweet Surely number one is avoiding..idiot neuro Snider L, Rodriguez E, Rains H, Peraza H, Montalvo M, Rempe T. Factors associated with delays in multiple sclerosis disease-modifying therapy initiation. Mult Scler J Exp Transl Clin. 2026;12:20552173261447996. doi: 10.1177/20552173261447996. PMID: 42112096; PMCID: PMC13153518. Background: In multiple sclerosis…
The post Caring Anyway <span>– Lindsay Kelly</span> appeared first on Multiple Sclerosis News Today. Source: multiplesclerosisnewstoday.com
Decode Health and Circular Genomics are partnering to use artificial intelligence (AI) to identify patterns in circular RNA — stable genetic molecules able to signal disease — that may help diagnose multiple sclerosis (MS) earlier and monitor its progression over time. The collaboration brings together…
Ocrevus (ocrelizumab) is an infusion therapy approved to treat adults with relapsing forms of MS and primary progressive MS. Administered via an intravenous infusion, the treatment is used to reduce the frequency of relapses, lower the number of lesions, and slow disability progression. The post…
The U.S. Food and Drug Administration (FDA) has formally agreed that the design and planned analysis of an upcoming Phase 3 trial testing privosegtor in people with optic neuritis could support a future application seeking the therapy’s approval if the trial succeeds. Optic neuritis, or…
Tweet Signori A, Montobbio N, Bovis F, Ponzano M, Schiavetti I, Krenn A, Sormani MP. Uncoupling Relapse Reduction and Disability Progression: Evidence From Tolebrutinib Studies. Neurol Clin Pract. 2026; 16:e200612. Objectives: The aim of this study was to evaluate whether the treatment effects of tolebrutinib on…